MORPHABOND ER Is a Single-Agent, Abuse-Deterrent Morphine

MORPHABOND ER Is a Single-Agent, Abuse-Deterrent Morphine1,2

FAMILIAR EFFICACY, SAFETY, AND DOSING

 

Bioequivalent to MS Contin®

FDA approved based on
efficacy and safety of MS Contin®
(reference listed drug)

A 1-to-1 conversion
MS Contin®

MORPHABOND ER With SentryBond Technology Is Formulated With Physical and Chemical Properties to Reduce Abuse1,2

The active ingredient—contained within a polymer matrix of inactive ingredients—is difficult to visibly distinguish or physically separate from the polymer matrix

  • Increased resistance to cutting, crushing, and/or breaking relative to MS Contin®
  • Resists extraction in selected household and laboratory solvents
    under various conditions including selected pretreatments
  • Forms a viscous material if physically compromised and
    placed in liquid
The graphic is for illustrative purposes only. It does not depict the actual tablet, polymer matrix, or active ingredient.

Retains its extended-release properties even if manipulated

Expected to deter abuse by both of the following routes:

Abuse of MORPHABOND ER is still possible by intranasal, intravenous, and oral routes
Abuse of MORPHABOND ER is still possible by intranasal, intravenous, and oral routes

Page navigation - About Morphabond ER

Clinical Abuse Potential Study

Review the data of MORPHABOND ER vs MS Contin® if manipulated and taken intranasally

Access the Interactive PI

Review the MORPHABOND ER
Prescribing Information

The MORPHABOND ER Savings Program

Eligible commercially insured patients may pay as little as $10 a month
Please see Eligibility Criteria and Terms and Conditions below.